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some metabolic disorders. Its main drawback, though, is the disparity between the number of donors and the patients need-
ing a liver graft. In this review we will discuss the recent changes regarding organ allocation, extended donor criteria, living
donor liver transplantation and potential room for improvement. The gap between the number of donors and patients need-
ing a liver graft forced the transplant community to introduce an objective model such as the modiﬁed model for end-stage
liver disease (MELD) in order to obtain a transparent and fair organ allocation system. The use of extended criteria donor
livers such as organs from older donors or steatotic grafts is one possibility to reduce the gap between patients on the wait-
ing list and available donors. Finally, living donor liver transplantation has become a standard procedure in specialized
centers as another possibility to reduce the donor shortage. Recent data clearly indicate that center experience is of major
importance in achieving good results. Great progress has been made in recent years. However, further research is needed to
improve results in the future.
 2008 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
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Over recent decades liver transplantation (OLT) has
become the mainstay for the treatment of patients with
decompensated liver cirrhosis, acute liver failure, hepa-
tocellular cancer (within the Milan criteria) and some
metabolic liver diseases. The major drawback of OLT
is the scarce supply of donor organs in relation to the
numbers of patients in need of OLT. According to the0168-8278/$34.00  2008 European Association for the Study of the Liver.
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Abbrevations: OLT, orthotopic liver transplantation; LDLT, living
donor liver transplantation; DDLT, deceased donor liver transplan-
tation; NHBD, non-heart beating donor; DCD, donation after cardiac
death; PNF, primary non-function; IPF, initial poor function.most recent UNOS Data 6650 liver transplants were
performed in 2006 and at the same time 17,221 patients
were listed on the waiting list. This disparity is certainly
the biggest challenge for the transplant community. We
have to ensure that the scarce organ pool is oﬀered to
the ones who need it most, while at the same time trying
to close this gap in available grafts. In this review, we
will discuss the changes that have taken place over the
last few years regarding organ allocation and assess
the recent changes in our understanding of extended cri-
teria donors and living donor liver transplantation.2. Organ allocation
The disparity between the number of donors and
recipients which increased in most countries over the
last decade, forced the transplant community to
develop a system to prioritize the large number ofPublished by Elsevier B.V. All rights reserved.
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of donors. In the US the allocation was initially based
on hospital status of the patient, where patients in an
intensive care unit received priority over patients hospi-
talized in a non-ICU unit and outpatients, and on the
accumulated waiting time. With only three categories,
the waiting time became of utmost importance in the
allocation process, leading to the often, yet unnecessary
listing of patients in the compensated stage just to start
gaining waiting time [1]. Later the criteria were modi-
ﬁed by ﬁrst introducing minimal listing criteria. These
criteria were based on the Child–Turcotte–Pugh
(CTP)-score and required a minimum of 7 points for
patients to be listed [2]. However, these criteria had
no signiﬁcant impact on the number of patients listed
and waiting time remained the most important factor
determining organ allocation. The fact that waiting list
mortality did not correlate with waiting time but with
disease severity suggested that waiting time should no
longer be the most important criteria for organ alloca-
tion [3]. Whereas in the US organ allocation was
always patient-based, in other countries such as Swit-
zerland organ allocation was or still is center-based
[4]. In some countries such as US and Switzerland,
the transplant community was forced by law makers
and politicians to rethink their allocation process
[4,5]. In the new rules and regulations a major empha-
sis is placed on the patient’s medical needs and less on
local factors with the ultimate goal of reducing waiting
list mortality. This search for a better allocation system
led ﬁnally to the introduction of a modiﬁed model for
end-stage liver disease (MELD score) by UNOS in
2002 to prioritize patients on the waiting list for liver
transplantation. The MELD score is based on three
objective biochemical parameters, which are readily
available in each hospital. These variables are serum
bilirubin, serum creatinine and the international nor-
malized ratio (INR) of prothrombin time. Initially this
score was developed to predict survival in patients
undergoing transjugular intrahepatic portosystemic
shunt (TIPS) [6]. This model was later validated in a
large group of patients with chronic liver disease and
the results suggested that this model can accurately
predict 3-month mortality, independently of aetiology
and complications of portal hypertension such as spon-
taneous bacterial peritonitis, hepatic encephalopathy
and variceal bleeding. Therefore, the score could be
used for organ allocation [7–9]. It was however recog-
nized early on, that the MELD score does not accu-
rately predict mortality of all diseases, which are
currently treated by liver transplantation [10]. This is
true not only for patients with hepatocellular cancer,
but also for patients with familial amyloidosis, meta-
bolic diseases and hepato-pulmonary syndromes. For
these patients a ‘‘MELD score equivalent” must be
assigned to assure timely transplantation.2.1. MELD-based organ allocation
The introduction of the MELD score in the US was a
success story and convinced other organizations such as
Euro- and Swisstransplant to change to the MELD
score as their liver allocation tool. A thorough analysis
of the US data convincingly showed that the introduc-
tion of the MELD score was associated with a 12%
reduction of new registrations to the liver transplant
waiting list, a 3.5% reduction in waiting list mortality
and identical posttransplant survival [11]. The survival
beneﬁt of liver transplantation was addressed in a large
study by Merion et al. [12]. They analyzed waiting list
and post-transplant mortality in cohort of almost
13,000 adult patients put on a US waiting list from
2001 to 2003. The mortality for transplant recipients
with a MELD-score >18 was signiﬁcantly reduced com-
pared to patients not transplanted and this beneﬁt con-
tinued to increase up to MELD 40. However, patients
transplanted with a MELD score <15 did not have a
demonstrable survival beneﬁt within a 1 year posttrans-
plant follow-up period. The MELD category of 15–17
represents a grey zone.
HCC is one of the diagnoses, where the MELD score
does not reﬂect the urgency for transplantation. There-
fore, it was important to assess, whether the arbitrarily
assigned MELD score provided adequate timing before
tumor progression precluded liver transplantation. It
was reassuring to realize that the MELD system also
had a beneﬁcial eﬀect on HCC liver transplant candi-
dates [13]. In the MELD area, waiting time and dropout
rate for HCC patients decreased, the number of patients
transplanted with HCC increased and the overall sur-
vival remained unchanged.
2.2. Potential room for improvement
Although these data clearly show that the introduc-
tion of the MELD had a positive eﬀect on organ alloca-
tion, the MELD score is not yet the holy grail of organ
allocation [10]. The replacement of the CTP-score with
the two subjective parameters ascites and encephalopa-
thy through the MELD score with three objective labo-
ratory parameters is certainly a step forward. However,
the MELD score also heavily depends on the reproduc-
ibility of the laboratory determinations from institution
to institution. It has been demonstrated that variability
in the determinations of the laboratory values used to
calculate the MELD score, most notably INR determi-
nation, could lead to changes in the MELD score of
up to 20% or changes in the priority from the 58th to
the 77th percentile [14]. Apart from the INR also the
serum creatinine determinations can be aﬀected by the
type of assay used to measure it and especially the serum
bilirubin concentration [15]. The interference from bili-
rubin results in lower serum creatinine concentrations
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centration, i.e. in patients with more advanced liver dis-
ease. Therefore, to reduce variability of laboratory
parameters, standardizations of laboratory assays to
measure INR and serum creatinine should be made
mandatory by organ allocation agencies using the
MELD system.
In an attempt to improve the MELD score, several
studies suggested that serum sodium in addition to the
MELD parameters might be an additional important
parameter to predict waiting list mortality [16–18]. More
recently, a prospective database was created to validate
and reﬁne the MELD model [19]. They observed a linear
increase of mortality with decreasing serum sodium con-
centration and therefore incorporated serum sodium
into a new MELD-Na score, which might provide a
more accurate prediction of survival.
The MELD score only focuses on recipient character-
istics and does not take into consideration any donor
criteria (see extended criteria donors). Several recent
publications however convincingly showed that quite a
few donor factors such as age, gender, race, graft type
(whole versus split liver graft), and ischemia time can
aﬀect posttransplant survival [20,21]. Since all these fac-
tors are not incorporated in the MELD score, it is not
surprising that a recent systematic review of MELDTable 1
Signiﬁcant donor risk factors
Signiﬁcant donor risk factors 5 Donor and 2 transplant risk factors iden
in the US [33]
Risk factor Increased risk of
Reference value Relative risk
Age Age <40 61–70: 1.53
>70: 1.65
Race White African American
Size Height Increase by 1.07 p
decrease in height
Cause of donor death Cause of donor
death: Trauma
CVAa: 1.16
Otherb: 1.20
DCDc: 1.51
Type of graft Full graft Partial/split: 1.52
BMI ns
Graft appearance No data
Diabetes ns
Transplant risk factors
Cold ischemia time Cold ischemia time Increase of 1.01 p
Sharing outside local area Local area Same region: 1.11
National: 1.28
ns, not signiﬁcant; nr, not reported.
a Cerebrovascular accident.
b Cause of death not trauma, cerebrovascular accident or anoxia.
c Donation after cardiac death.score concluded that this score is not able to predict
mortality after liver transplantation [22].
Further reﬁnements of the system, such as standard-
ization of laboratory procedures, incorporation of new
parameters such as sodium and maybe donor and recipi-
ent matching might further improve the allocation pro-
cess and optimize justice and utility at the same time.3. Extended criteria donor
As mentioned earlier, a major challenge for the trans-
plant community is to develop strategies to close the gap
between the number of patients in need of a transplant
and the number of available organs. Among others, this
includes increasing the donation rate, developing living
donor liver transplant programs or new surgical tech-
niques such as split liver transplantation and ﬁnally
using organs that were previously thought to be associ-
ated with an unacceptably high risk of primary non-
function (PNF) or initial poor function (IPF), so called
extended criteria donors [23]. An accepted deﬁnition of
extended criteria donor livers has not yet been estab-
lished by the liver transplant community. However, sev-
eral risk factors (Table 1) that are associated with an
increased rate of PNF or IPF have been identiﬁed [24].tiﬁed 6 Donor and 1 transplant risk factor identiﬁed in the
UK [47]
graft failure Risk factor Increased risk of graft failure
Reference value Relative risk
Age Increase by 1.05 per decade
: 1.19 White Non-white: 2.17
er 10 cm nr
nr
Full graft Reduced/split: 1.93
BMI Increase by 1.01 per unit
increase in BMI
Normal Suboptimal: 1.31
No diabetes Diabetes: 1.41
er hour Cold ischemia time Increase of 1.02 per hour
nr
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Donor age steadily increased over recent decades. In
1994, only 20% of deceased donors were 50 years or
older. This precentage increased by more than 150% in
the year 2004 [25–27]. Although some studies suggested
that donors older than 50 years without additional risk
factors have similar outcomes compared to younger
donors [28–32], more recent studies using the large dat-
abases of either SRTR/UNOS or ELTR clearly identi-
ﬁed donor age as an important risk factor for poor
outcome after liver transplantation [20,21,33].
3.2. Donor gender, weight, height and race
Even though the donor gender has been identiﬁed as
a risk factor for post-OLT outcome in some studies [21],
this could not be conﬁrmed by others [33]. Race, how-
ever, consistently seems to aﬀect recipient outcome
[21,33]. Interestingly, of the two parameters reﬂecting
donor size, only height but not weight was indepen-
dently associated with recipient outcome [33].
3.3. Cause of donor death
In the early years of liver transplantation the typical
cause of death of an organ donor was related to cerebral
trauma. In more recent years cerebral trauma as a cause
of death of organ donors has gradually decreased, while
cerebrovascular causes increased [34]. According to the
study by Feng et al. cause of death other than trauma
was associated with a 16% (cerebrovascular accident)
and 20% (other causes) increased risk of graft failure,
respectively [33].
The success of renal transplantation from non-heart
beating donors (NHBDs) also referred to as donation
after cardiac death (DCD) has led to a renewed interest
in the liver transplant community as a potential way to
increase the donor pool [35–37]. NHBDs are divided
into controlled and uncontrolled group in order to
underline diﬀerences in clinical practice, graft outcome,
ethics and future potential [38]. Controlled donation
occurs in an intensive care unit in a controlled environ-
ment, whereas in uncontrolled donation the donor death
occurs either outside the hospital or in the emergency
room following an unsuccessful attempt of resuscitation
[38]. In controlled NHBD warm ischemia time can be
accurately assessed, cold ischemia can be minimized
and it is estimated that the donor liver pool could be
increased by as much as 20% [39]. The results of con-
trolled NHBD approach those of heart-beating-dona-
tion, but vascular and biliary complications might still
be higher for a recipient of a DCD graft [40–42]. In
addition, in the large analysis of donor risk factors by
Feng et al. DCD was associated with a 51% increased
risk of graft failure [33]. New techniques for liver pro-curement, which are currently tested in experimental set-
tings, are urgently needed to optimize DCD [43].
3.4. Graft steatosis
Considering the current epidemic of adipositas in
developed countries, it is obvious that more and more
liver grafts will be steatotic. The transplant community
will be forced to provide guidelines on how to use these
grafts safely. Steatosis has been traditionally classiﬁed
according to morphology as macrovesicular or microve-
sicular and according to quantiﬁcation as mild, moder-
ate or severe if less than 30%, 30–60% or more than
60% of hepatocytes are aﬀected [44,45]. The assessment
of a donor organ is one of the most diﬃcult tasks for the
transplant team. While macroscopic examination
appears to be fairly reliable in determining the presence
of severe grades of steatosis, it fails to detect moderate
and mild degrees [46]. Although macroscopic inspection
is very subjective, in a recent publication in abstract
form, inspection of the graft (suboptimal versus normal)
was identiﬁed as a signiﬁcant risk factor for graft loss
[47]. When steatosis is suspected at inspection, 38% of
liver transplant surgeons in the UK and 47% in the
US proceed to histological examination of the graft. In
spite of the low overall positive predictive value of mac-
roscopic assessment, 50% of UK transplant surgeons
never integrate histopathologic assessment into their
decision-making process [48]. While the same survey
indicated a much higher use of biopsies in the US, cur-
rent OPTN data (as of April 14, 2006) reveal that only
27.8% of all 7593 cadaveric livers considered for OLT
in 2005 were actually biopsied [49]. Although micro-
scopic examination remains the ‘‘gold standard”, diﬀer-
ent tissue processing and staining techniques can aﬀect
detection and grading of steatosis [50]. Data on the clin-
ical relevance of fat detected by more sensitive stains are
still lacking and there is currently no consensus on how
to assess the degree of steatosis in a liver graft.
There is no question that mildly steatotic grafts can
be accepted for liver transplantation [49]. In contrast,
assignment of moderately steatotic grafts (between
30% and 60%) is still controversial. There is current
agreement that moderately steatotic grafts qualify as
extended criteria grafts because they have been associ-
ated with poor clinical outcome, particularly when asso-
ciated with additional risk factors [46]. While some
investigators have reported increased rates of PNF
(13% versus 3%) [51], others found identical 1-year graft
and patient survival when transplanting livers with mod-
erate steatosis and non-fatty livers, respectively [46,52–
54]. Recent studies therefore conclude that grafts with
moderate steatosis can be safely used in low risk
patients, whereas they should be discarded for recipients
with a high MELD score [49,55]. However, primary
dysfunction was unanimously more common in the
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graft dysfunction on long-term graft outcome is still
unclear.
A recent report from our center opened the debate
about the use of severely steatotic grafts [56]. In a case
control study of 20 patients with severely steatotic grafts
(90% liver steatosis) and 40 matched controls 60-day
mortality (5% versus 5%) and 3-year patient survival
rate (83% versus 84%) were comparable between the
control and severe steatotic group. Our study challenges
the dogma that liver grafts with severe steatosis should
be discarded for all recipients, but this ﬁnding certainly
needs to be conﬁrmed by other studies.
3.5. Type of graft
Although split liver transplantation is well estab-
lished in pediatric patients, its role in adult patients is
still controversial. A recent match pair analysis of
patients after whole versus split liver transplantation
using an extended right liver lobe found no diﬀerence
in neither short nor long-term morbidity or mortality
[57]. Others, however, showed an inferior graft survival
rate for recipients of the left graft [58]. This is supported
by the recent analysis of the large SRTR database,
where split or partial grafts were associated with 52%
higher risk of graft failure [33].
3.6. Cold ischemia
One of the major reasons for graft dysfunction is
undoubtedly ischemic injury to the graft. More than
14 h of cold ischemia has been consistently associated
with an increased preservation damage associated with
a prolonged postoperative course, biliary strictures and
decreased graft survival [59–61]. Accordingly, the risk
of graft loss increases by 1% for each additional hour
of cold ischemia [33].
3.7. Other factors
The role of several other risk factors identiﬁed in dif-
ferent studies such as obesity, elevated liver functions
tests, hypotension or increased vasopressor use and
hypernatremia [24] is less clear, as they were not associ-
ated with an increased risk of graft failure in the most
recent study [33].
3.8. How to translate this into clinical practice
In a large retrospective study by Feng et al. including
data from more than 20,000 donor from the US Cox
regression models identiﬁed 5 donor characteristics
(Age, race, donor height, donor death (Cerebrovascular
accident (CVA), causes of death other than trauma,
stroke or anoxia and donation after cardiac death(DCD)) and type of graft (partial/split graft)) that inde-
pendently predicted a signiﬁcantly increased risk graft
failure [33] (Table 1). In addition, they recognized two
transplant-related factors (cold ischemia time and shar-
ing outside of the local donor service area), which were
also signiﬁcantly associated with graft loss [33]. All these
factors were used to generate a donor risk index, which
is directly related to a predicted rate of graft survival. In
a very similar study from the United Kingdom, which is
so far only published in abstract form, Dawwas et al.
also identiﬁed 7 slightly diﬀerent risk factors for graft
loss [47] (Table 1). These could also be used to calculate
a donor risk index. In the UK setting, the UK donor
risk score outperformed the US donor risk score [47].
However, both scores need to be externally validated
in other populations before ﬁrm recommendations
about their use can be made. Nevertheless, together with
the MELD model, which assesses the risk of death of the
recipient on the waiting list, we now also have tools, that
provide us with prognostic information about the graft.
Unfortunately the donor risk index is only an estimate
for the average patient on the waiting list and not yet
applicable to speciﬁc patient population. So far, only
the Markov models suggest that for patients with
MELD score greater than 20, immediate transplantation
even with grafts that carry a risk as high as 50% for a
primary graft failure is still associated with a survival
beneﬁt [62]. However, we eagerly await reports which
are based on real data and not on modeling approaches.4. Living donor liver transplantation (LDLT)
Living donor liver transplantation (LDLT) has been
one of the other options to expand the scarce donor pool
[63,64]. Initially, the recipients in LDLT were mostly
children, but with growing expertise with right lobe
donation, LDLT today is also a valuable option for
adult recipients [65].
4.1. Donor selection
Appropriate donor evaluation is one of the most cru-
cial parts in LDLT [65]. The goal of the evaluation pro-
cess is to exclude donors with an increased risk for
morbidity and mortality, while at the same time assuring
that a suitable graft for the recipient can be obtained. In
a recent large retrospective study from the US the char-
acteristics and acceptance rate of donor candidates
(n = 1011) was evaluated over a period of 5 years [66].
In total, the acceptance rate for donor candidates was
40%. It is interesting to note that donor acceptance rate
dropped signiﬁcantly from 47% (1998–2000) to 35%
(2001–2003). Similar data have already been reported
from single center experiences, with acceptance rates as
high as 63% for the period 1997–2001 compared to only
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decline is not entirely clear, but could be related to the
highly publicized donor death in the US or diﬀerences
in the allocation process after introduction of the
MELD system. Even higher donor rejection rates are
reported from Europe (86%) [68], whereas this rate is
considerably lower in Japanese centers [69,70]. The
strongest predictors of donor acceptance in the recent
US study were in decreasing order of signiﬁcance: center
of evaluation, donor BMI, year of evaluation, recipient
MELD-score, days from listing to ﬁrst-donor evalua-
tion, recipient age, donor–recipient relatedness and
donor age. Surprisingly, only donor BMI, donor age
and relatedness were donor-speciﬁc factors inﬂuencing
the acceptance rate, whereas the strongest predictor
was neither donor nor recipient-related. This suggests
that other currently less well deﬁned ‘‘local” factors play
an important role in the donor acceptance process.
4.2. Donor outcome
The goal of the donor evaluation process is to assure
a safe outcome for the donor. But even with the best
evaluation process complications and even death cannot
be completely avoided. Currently, over 3500 adult to
child and over 2500 adult to adult living donor liver
transplantations have been performed worldwide. In a
recent systematic review of more than 300 articles cover-
ing approximately 6000 LDLT procedures, it is esti-
mated that the donor mortality is approximately 0.2%
[71]. Mortality is higher for adult to adult (0.24–0.4%)
compared to adult to child donation (0.09–0.2%). This
is explained by the fact that adult to adult donation
mostly encompasses a right lobe and adult to children
mostly a left lobe donation. Left lobe donation has been
associated with a lower mortality (0.05–0.21%), com-
pared to right lobe (0.23–0.5%) [71].
Reporting of morbidity is unfortunately not stan-
dardized, explaining the huge range from 0% to 100%
with an average morbidity of 16.1% [71]. The most com-
mon complications are biliary complications and infec-Table 2
Classiﬁcation of complications (for details see Ref. [76])
Dindo et al. [73]
Grade 1 Any deviation from normal course requiring no pharmacol
Grade 2 Requiring pharmacologic treatment with other than those
Grade 3 Requiring surgical, endoscopic or radiological intervention
(a) not under general anesthesia
(b) under general anesthesia
Grade 4 Life-threatening complications requiring ICU management
(a) single organ dysfunction
(b) multiorgan dysfunction
Grade 5 Death of patienttions. The median biliary complication rate was 6.2%
(range: 0–38.6%). Infections were mostly wound or uri-
nary tract infections with a median rate of 5.8% (range
0–28.6%). To better standardize the reporting of donor
morbidity the Vancouver Forum on the care of the live
organ donor recently proposed to use the Clavien or
modiﬁed Clavien system to record and grade live donor
complications by severity [72–74]. The recently intro-
duced modiﬁed classiﬁcation still mostly relies on the
therapy used to treat the complication but four impor-
tant modiﬁcations to increase its reliability and potential
use in the surgical literature were introduced [73] (Table
2). First, life-threatening complications requiring an
intermediate or intensive care management (IC/ICU)
were diﬀerentiated from complications treated on the
ward. Secondly, complications involving the central ner-
vous system (e.g. ischemic stroke, brain hemorrhage,
subarachnoidal bleeding) were also considered as grade
IV complications. Third, the length of hospital stay is no
longer considered in the ranking of complications and
fourth, the presumed long-term consequences of a com-
plication are integrated in the new classiﬁcation. This
new classiﬁcation was used to retrospectively evaluate
the complication rate from two large healthcare regis-
tries involving 433 right and left lobe donors from 13
centers in the US between 2001 and 2005 [75]. There
was one perioperative death (0.23%) and the overall
complication rate was 29.1%. The major complication
rate (Clavien grade P3) was 3.5%. Risk factors for
lower overall complication rate were center living donor
volume (OR = 0.97; 95% CI = 0.95–0.99) and ratio of
living donors to all donors (OR: 0.94, 95% CI = 0.92–
0.99). The only risk factor associated with major compli-
cations was donor age over 50 (OR: 4.25, 95%
CI = 1.22–14.97). In our current experience involving
19 donor operations, we observed one major complica-
tion (Grade 3a), three grade I and II each and in 12 cases
the outcome was completely uneventful (Clavien et al.,
unpublished data).
In contrast to somatic complications, psychiatric
complications of the donor are not nearly as well stud-ogic treatment except: antiemetic, antipyretic, analgesics and diuretics
allowed for grade 1
(including central nervous system complications)
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tion cohort study (A2ALL) recently reported the type
and prevalence of severe psychiatric complications in
392 donors enrolled in the A2ALL study [76]. During
a median postoperative follow-up of 6 months (range:
3 days–5.6 years) 16 patients (4.1%) developed one or
more psychiatric complications, including 3 severe (sui-
cide, dead after accidental drug overdose and suicide
attempts). All recipients of the three donors with severe
complications were alive and well at the time of these
events. So far, the focus has centered on surgical compli-
cations in the early postoperative period, but these data
clearly underline the need for a careful psychiatric pre-
donation work-up and also for a regular long-term fol-
low-up of donors to fully appreciate the full burden of
complications associated with living donation.
4.3. Recipient selection
All recipients should be listed on a national waiting
list and indications for LDLT should be the same as
those established for deceased donor liver transplanta-
tion. Therefore, every patient eligible for cadaveric liver
transplantation is also a candidate for LDLT. In addi-
tion, the Vancouver Forum stated that the expected
graft and patient survival of LDLT should be approxi-
mately the same as for a recipient of a deceased donor
transplant with the same disease [74]. It has been recog-
nized early on that patients with severely decompensated
liver disease do not tolerate LDLT very well [77]. In
patients with chronic liver disease and severe decompen-
sation (MELD > 30) the long-term mortality following
LDLT (57%) was signiﬁcantly higher compared to
deceased donor transplant (18% historical control)
[78,79]. Therefore, it has been recommended not to oﬀer
LDLT to donors with a MELD score >25 [80]. This pol-
icy is also reﬂected in the recent report from the A2ALL
consortium, which retrospectively analyzed the outcome
of 384 adult to adult living donor liver transplant recip-
ients [81]. In this report the mean MELD score at the
time of transplant was 15.6 ± 6.9 (range 6–40), com-
pared to a mean MELD score of 22 in deceased donor
liver transplantation. Only 4% had a MELD score
greater than 30 points and 4% were patients with fulmin-
ant liver failure.
The major advantage of LDLT is to shorten waiting
time. Therefore, patient groups with an urgent need for
liver transplantation or whose disease severity is not well
reﬂected by the MELD score seem to be prime candi-
dates for LDLT [80]. Part of the ﬁrst group are patients
with HCC, who could beneﬁt from fast-track transplan-
tation, even with current prioritization through the cor-
rected MELD score. To the latter belong patients with
mostly cholestatic liver disease and severe pruritus or
patients with ascites and/or encephalopathy, but still
well-preserved liver function.4.4. Recipient outcome
Although LDLT recipients have a shorter waiting
time, initial reports suggested that LDLT recipients
had a higher graft failure rate (hazard rate 1.66) [82]
and a 10% lower graft survival rate after 2 years associ-
ated with a 60% higher likelihood of graft loss [83].
However, a recent retrospective analysis of the A2ALL
study group clearly showed, that graft failure rate corre-
lated with experience; i.e. centers with more than 20
LDLT had a signiﬁcantly lower graft failure risk [81].
Accordingly, more recent studies reported similar
patient survival rates among living donor and deceased
donor liver transplant recipient [84]. Reduced waiting
time is the big advantage of LDLT and this obviously
could also impact on patient survival. This was
addressed in a recent study by Shah et al. that analyzed
the outcome of LDLT from the time of listing and not
from the time of transplant [85]. In their large study with
144 LDLT and 350 DDLT recipients, they could show
that LDLT recipients had a signiﬁcant survival advan-
tage over DDLT after 1 year (90% 1-year survival com-
pared to 80%). Direct comparison of survival rates is,
however, problematic, since MELD-scores at the time
of transplant are in general signiﬁcantly higher in the
DDLT group compared to the LDLT group. This was
also true for study by Shah et al. Although MELD-
scores at the time of listing were similar, the LDLT
group had a signiﬁcantly lower MELD at the time of
transplant. Very similar results were obtained by a
recent study of the A2ALL study group [86]. In their
analysis, the relative mortality risk of LDLT was only
56% compared to DDLT (p < 0.001). As previously
reported in other studies, the beneﬁt of LDLT depended
on experience and was lower (Hazard ratio: 0.83) in the
less experienced period (<20 LDLT) compared to the
more experienced period (Hazard ratio: 0.35,
p < 0.001). In this study, early re-transplantation
(3 weeks) was necessary in 1.1% of DDLT recipients
and 7.8% and 3.6% of LDLT recipients in the less and
more experienced period, respectively.
4.5. Recipient complications
Most complications are similar in LDLT and DDLT
recipients. However, it has been consistently shown that
biliary complications are more frequent in LDLT com-
pared to DDLT recipients, occurring still in 24–67%
(for review see ref [87]). Possible risk factors associated
with an increased risk of postoperative biliary complica-
tions included multiple ductal openings [88], a high pre-
operative model for end-stage liver disease score (P35)
[89] and older donor age and previous history of a bile
leak [90]. Whereas initially more Roux-en-Y (R–Y)
anastomoses were performed, today most authors would
agree that duct to duct anastomosis is safe and has the
B. Mu¨llhaupt et al. / Journal of Hepatology 48 (2008) S58–S67 S65advantage of providing access for future endoscopic
therapy in cases of leak or stricture. This increased com-
plication rate also leads to higher hospitalization rates in
LDLT recipients [91]. In the ﬁrst year the increased
number of hospitalizations was due to biliary and non-
biliary complications, whereas after the ﬁrst year, these
were mostly because of biliary complications.
4.6. LDLT in patients with chronic hepatitis C
Liver cirrhosis due to chronic hepatitis C is the most
common indication for liver transplantation in most
countries. Therefore, the outcome of this patient group
after LDLT was of special interest. Initial reports sug-
gested that HCV recurrence in LDLT recipients might
be faster and more severe, whereas these diﬀerences were
no longer consistently observed in more recent studies
(for review see ref [92,93]). Comparison of the results
is however diﬃcult, since the deﬁnition of HCV recur-
rence, the use of protocol biopsies and antiviral treat-
ment before and after transplantation diﬀer widely
between studies. The large retrospective analysis by the
A2ALL study group of 181 living donor liver transplant
(LDLT) recipients and 94 deceased donor liver trans-
plant (DDLT) recipients with chronic hepatitis C
showed a 3-year graft and patient survival of 68% and
74% in LDLT compared to 80% and 82% in DDLT,
respectively [94]. The diﬀerence for graft survival but
not patient survival being signiﬁcantly lower in the
LDLT group compared to the DDLT group
(p = 0.02). However, if adjusted for experience of the
center (>20 LDLT) 3-year graft survival for DDLT
and LDLT with more than 20 procedures was no longer
signiﬁcantly diﬀerent (80% versus 79%). Predictors of
graft loss beyond 90 days included LDLT 6 20 (Hazard
ratio = 2.1, p = 0.04), pre-transplant hepatocellular car-
cinoma (HCC) (HR = 2.21, p = 0.03) and severity of
liver disease, i.e. model for end-stage liver disease
(MELD) at transplantation (HR = 1.24, p = 0.04).
4.7. Conclusions
The introduction of the MELD scoring system
undoubtedly improved the allocation process. It will
be interesting to see whether the combination of the
MELD score with a donor risk index might further
reﬁne the liver allocation process. In this regard a better
understanding of the impact of extended criteria donors
and especially steatosis on outcome will be crucial. A
prerequisite to better understand the impact of graft ste-
atosis on outcome will be to obtain routine donor liver
biopsy at the time of harvest. Unfortunately, these data
are currently lacking in most large donor databases. It
has become clear that experience in LDLT signiﬁcantly
aﬀects outcome, therefore it might be advisable to
restrict LDLT to a limited number of centers.References
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